Available at: Updated Cervical Cancer Screening Guidelines, href="https://jamanetwork.com/journals/jama/fullarticle/2697704, https://academic.oup.com/ajcp/article/137/4/516/1760450, https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/10/updated-guidelines-for-management-of-cervical-cancer-screening-abnormalities, https://journals.lww.com/jlgtd/Fulltext/2020/04000/2019_ASCCP_Risk_Based_Management_Consensus.3.aspx, https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21628, : https://jamanetwork.com/journals/jama/fullarticle/2697702, https://jamanetwork.com/journals/jama/fullarticle/2697703, https://www.cdc.gov/cancer/hpv/statistics/cervical.htm, https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.30507, https://www.sciencedirect.com/science/article/abs/pii/S0027968420300432, https://gh.bmj.com/content/4/3/e001351.long, https://jamanetwork.com/journals/jamaoncology/fullarticle/2554749, https://www.cdc.gov/mmwr/volumes/70/wr/mm7012a2.htm, https://www.cdc.gov/mmwr/volumes/69/wr/mm6933a1.htm, https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination/increase-proportion-adolescents-who-get-recommended-doses-hpv-vaccine-iid-08, https://www.tandfonline.com/doi/abs/10.1080/13557858.2018.1427703, https://www.liebertpub.com/doi/10.1089/jwh.2018.7380, https://www.cdc.gov/mmwr/volumes/70/wr/mm7002a1.htm, https://journals.sagepub.com/doi/10.1177/0033354920925094, https://journals.lww.com/greenjournal/Fulltext/2020/08000/Human_Papillomavirus_Vaccination__ACOG_Committee.48.aspx, Alliance for Innovation on Women's Health, Postpartum Contraceptive Access Initiative. recommended for patients at progressively higher risk, while those at lower risk can defer colposcopy, undergo There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits. For more information on the USPSTF grades, see https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions Primary hrHPV testing is FDA approved for use starting at age 25 years, and ACOG, ASCCP, and SGO advise that primary hrHPV testing every 5 years can be considered as an alternative to cytology-only screening in average-risk patients aged 2529 years.